Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark L Moster

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
JAMA Ophthalmology|December 19, 2024
Five-Year Outcomes of Lenadogene Nolparvovec Gene Therapy in Leber Hereditary Optic NeuropathyPatrick Yu-Wai-Man, Nancy J Newman, Valérie Biousse, et al.
Journal of Neuro-Ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society|August 20, 2021
Long-Term Follow-Up After Unilateral Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy: The RESTORE StudyValérie Biousse, Nancy J Newman, Patrick Yu-Wai-Man, et al.
Eye (London, England)|September 19, 2022
Geographic and socioeconomic access disparities to Phase 3 clinical trials in ophthalmology in the United StatesRebecca Russ Soares, Charles Huang, James Sharpe, et al.
Eye (London, England)|April 29, 2021
Natural history of patients with Leber hereditary optic neuropathy-results from the REALITY studyPatrick Yu-Wai-Man, Nancy J Newman, Valerio Carelli, et al.
Ophthalmology|January 16, 2021
Efficacy and Safety of Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy Treated within 6 Months of Disease OnsetNancy J Newman, Patrick Yu-Wai-Man, Valerio Carelli, et al.
Journal of Neuro-Ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society|July 26, 2021
Cross-Sectional Analysis of Baseline Visual Parameters in Subjects Recruited Into the RESCUE and REVERSE ND4-LHON Gene Therapy StudiesMark L Moster, Robert C Sergott, Nancy J Newman, et al.
American Journal of Ophthalmology|December 10, 2022
Safety of Lenadogene Nolparvovec Gene Therapy Over 5 Years in 189 Patients With Leber Hereditary Optic NeuropathyCatherine Vignal-Clermont, Patrick Yu-Wai-Man, Nancy J Newman, et al.
Frontiers in Neurology|June 10, 2021
Intravitreal Gene Therapy vs. Natural History in Patients With Leber Hereditary Optic Neuropathy Carrying the m.11778G>A <i>ND4</i> Mutation: Systematic Review and Indirect ComparisonNancy J Newman, Patrick Yu-Wai-Man, Valerio Carelli, et al.
Brain : a Journal of Neurology|November 9, 2022
Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathyNancy J Newman, Patrick Yu-Wai-Man, Prem S Subramanian, et al.
Science Translational Medicine|December 10, 2020
Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathyPatrick Yu-Wai-Man, Nancy J Newman, Valerio Carelli, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
JAMA Ophthalmology|December 19, 2024
Five-Year Outcomes of Lenadogene Nolparvovec Gene Therapy in Leber Hereditary Optic NeuropathyPatrick Yu-Wai-Man, Nancy J Newman, Valérie Biousse, et al.
Journal of Neuro-Ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society|August 20, 2021
Long-Term Follow-Up After Unilateral Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy: The RESTORE StudyValérie Biousse, Nancy J Newman, Patrick Yu-Wai-Man, et al.
Eye (London, England)|September 19, 2022
Geographic and socioeconomic access disparities to Phase 3 clinical trials in ophthalmology in the United StatesRebecca Russ Soares, Charles Huang, James Sharpe, et al.
Eye (London, England)|April 29, 2021
Natural history of patients with Leber hereditary optic neuropathy-results from the REALITY studyPatrick Yu-Wai-Man, Nancy J Newman, Valerio Carelli, et al.
Ophthalmology|January 16, 2021
Efficacy and Safety of Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy Treated within 6 Months of Disease OnsetNancy J Newman, Patrick Yu-Wai-Man, Valerio Carelli, et al.
Journal of Neuro-Ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society|July 26, 2021
Cross-Sectional Analysis of Baseline Visual Parameters in Subjects Recruited Into the RESCUE and REVERSE ND4-LHON Gene Therapy StudiesMark L Moster, Robert C Sergott, Nancy J Newman, et al.
American Journal of Ophthalmology|December 10, 2022
Safety of Lenadogene Nolparvovec Gene Therapy Over 5 Years in 189 Patients With Leber Hereditary Optic NeuropathyCatherine Vignal-Clermont, Patrick Yu-Wai-Man, Nancy J Newman, et al.
Frontiers in Neurology|June 10, 2021
Intravitreal Gene Therapy vs. Natural History in Patients With Leber Hereditary Optic Neuropathy Carrying the m.11778G>A <i>ND4</i> Mutation: Systematic Review and Indirect ComparisonNancy J Newman, Patrick Yu-Wai-Man, Valerio Carelli, et al.
Brain : a Journal of Neurology|November 9, 2022
Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathyNancy J Newman, Patrick Yu-Wai-Man, Prem S Subramanian, et al.
Science Translational Medicine|December 10, 2020
Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathyPatrick Yu-Wai-Man, Nancy J Newman, Valerio Carelli, et al.
Pageof 7